Quick Answer
Marker Therapeutics, Inc. reported Research And Development Expense of $11.80 million for the year ending 2025.
- Marker Therapeutics, Inc. showed a decrease of -12.4% in Research And Development Expense from 2024 to 2025.
- This data is from Marker Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2012: $115.5 thousand | Q2 2012: $245.8 thousand | Q3 2012: $71.1 thousand | Q1 2013: $243.0 thousand | Q2 2013: $54.4 thousand | Q3 2013: $30.0 thousand | Q1 2014: $22.5 thousand | Q2 2014: $22.5 thousand | Q3 2014: $32.5 thousand | Q1 2015: $609.4 thousand | Q2 2015: $201.2 thousand | Q3 2015: $968.8 thousand | Q1 2016: $985.8 thousand | Q2 2016: $1.25 million | Q3 2016: $1.11 million | Q1 2017: $989.1 thousand | Q2 2017: $1.20 million | Q3 2017: $1.62 million | Q1 2018: $1.60 million | Q2 2018: $1.83 million | Q3 2018: $1.88 million | Q1 2019: $2.83 million | Q2 2019: $3.15 million | Q3 2019: $3.12 million | Q1 2020: $3.82 million | Q2 2020: $4.28 million | Q3 2020: $4.80 million | Q1 2021: $5.64 million | Q2 2021: $7.35 million | Q3 2021: $6.78 million | Q1 2022: $7.03 million | Q2 2022: $2.92 million | Q3 2022: $3.59 million | Q1 2023: $3.38 million | Q2 2023: $2.38 million | Q3 2023: $2.04 million | Q1 2024: $2.58 million | Q2 2024: $2.34 million | Q3 2024: $3.47 million | Q1 2025: $3.14 million | Q2 2025: $4.18 million | Q3 2025: $2.35 million.
- Over the full 16 years of available data (2010 to 2025), Marker Therapeutics, Inc.'s Research And Development Expense has grown by 3,968.0%.
- Historical annual values: Fiscal year 2025: $11.80 million | Fiscal year 2024: $13.47 million | Fiscal year 2023: $10.42 million | Fiscal year 2022: $11.97 million | Fiscal year 2021: $27.79 million | Fiscal year 2020: $18.88 million | Fiscal year 2019: $12.76 million | Fiscal year 2018: $7.95 million | Fiscal year 2017: $5.25 million | Fiscal year 2016: $3.80 million | Fiscal year 2015: $1.71 million | Fiscal year 2014: $189.0 thousand | Fiscal year 2013: $697.6 thousand | Fiscal year 2012: $1.06 million | Fiscal year 2011: $203.7 thousand | Fiscal year 2010: $290.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: